A peptide inhibitor of cytomegalovirus infection from human hemofiltrate

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4751-4760

  Borst, Eva Maria ^a   Ständker, Ludger ^a   Wagner, Karen ^a   Schulz, Thomas F ^a   Forssmann, Wolf Georg ^a   Messerle, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINYLTYROSYLVALYLISOLEUCYLPROLINE; LYSINE; PEPTIDE DERIVATIVE; PROTEOHEPARAN SULFATE; SULFATE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BODY FLUID; CELL SURFACE; CELL TYPE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BINDING; DRUG INHIBITION; DRUG ISOLATION; DRUG MECHANISM; DRUG SULFATION; HEMOFILTRATE; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

BETA-THROMBOGLOBULIN; CYTOMEGALOVIRUS; FLUOROMETRY; HEPARAN SULFATE PROTEOGLYCANS; HERPESVIRUS 1, HUMAN; HUMANS;

EID: 84884264891     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00854-13     Document Type: Article

References (61)

1. Mocarski E, Shenk T, Pass R. 2007. Cytomegaloviruses, p 2702-2772. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott, Williams & Wilkins, Philadelphia, PA.
2. Kedhar SR, Jabs DA. 2007. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 14:66-71.
3. Britt W. 2008. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 325:417-470.
4. Fisher RA. 2009. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl. Infect. Dis. 11:195-202.
5. Ljungman P, Hakki M, Boeckh M. 2010. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect. Dis. Clin. North Am. 24: 319-337.
6. Dollard SC, Grosse SD, Ross DS. 2007. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. 17:355-363.
7. Gallo RL, Murakami M, Ohtake T, Zaiou M. 2002. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol. 110:823-831.
8. Ganz T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3:710-720.
9. Schepky AG, Bensch KW, Schulz-Knappe P, Forssmann WG. 1994. Human hemofiltrate as a source of circulating bioactive peptides: determination of amino acids, peptides and proteins. Biomed. Chromatogr. 8:90-94.
10. Schulz-Knappe P, Magert HJ, Dewald B, Meyer M, Cetin Y, Kubbies M, Tomeczkowski J, Kirchhoff K, Raida M, Adermann K, Kist A, Reinecke M, Sillard R, Pardigol A, Uguccioni M, Baggiolini M, Forssmann WG. 1996. HCC-1, a novel chemokine from human plasma. J. Exp. Med. 183: 295-299.
11. Schulz-Knappe P, Schrader M, Ständker L, Richter R, Hess R, Jurgens M, Forssmann WG. 1997. Peptide bank generated by large-scale preparation of circulating human peptides. J. Chromatogr. A 776:125-132.
12. Forssmann WG, Schulz-Knappe P, Meyer M, Adermann K, Forssmann D, Hock D, Aoki A. 1992. Characterization of natural postranslationally processed peptides from human blood: a new tool in the systematic investigation of native peptides, p 553-557. In YanaiharaN(ed), Peptide chemistry. Escom, Leiden, The Netherlands.
13. Richter R, Schulz-Knappe P, Schrader M, Ständker L, Jurgens M, Tammen H, Forssmann WG. 1999. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B Biomed. Sci. Appl. 726:25-35.
14. Detheux M, Ständker L, Vakili J, Münch J, Forssmann U, Adermann K, Pöhlmann S, Vassart G, Kirchhoff F, Parmentier M, Forssmann WG. 2000. Natural proteolytic processing of hemofiltrateCCchemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J. Exp. Med. 192:1501-1508.
15. Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F. 2007. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129:263-275.
16. Münch J, Rucker E, Ständker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Gimenez-Gallego G, Sanchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F. 2007. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131:1059-1071.
17. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B. 2008. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 89:359-368.
18. Borst EM, Messerle M. 2000. Development of a cytomegalovirus vector for somatic gene therapy. Bone Marrow Transplant. 25(Suppl 2):S80-S82.
19. Mathys S, Schroeder T, Ellwart J, Koszinowski UH, Messerle M, Just U. 2003. Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation. J. Infect. Dis. 187:988-999.
20. Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, McMahon M. 2002. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp. Cell Res. 273: 21-33.
21. Brune W, Hengel H, Koszinowski UH. 2001. A mouse model for cytomegalovirus infection, p 19.7.1-19.7.13. In Coligan JE, Bierer B, Margulies DH, Shevach EM, Strober W, Coico R (ed), Current protocols in immunology. John Wiley & Sons, New York, NY.
22. Esko JD, Stewart TE, Taylor WH. 1985. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 82:3197-3201.
23. Borst EM, Benkartek C, Messerle M. 2007. Use of bacterial artificial chromosomes in generating targeted mutations in human and mouse cytomegaloviruses, p 10.32.1-10.32.30. In Coligan JE, Bierer B, Margulies DH, Shevach EM, Strober W, Coico R (ed), Current protocols in immunology. John Wiley & Sons, New York, NY.
24. Borst EM, Messerle M. 2005. Analysis of human cytomegalovirus oriLyt sequence requirements in the context of the viral genome. J. Virol. 79: 3615-3626.
25. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
26. John H, Hierer J, Haas O, Forssmann WG. 2007. Quantification of angiotensin-converting-enzyme-mediated degradation of human chemerin 145-154 in plasma by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Anal. Biochem. 362:117-125.
27. Merrifield B. 1985. Solid phase synthesis. Nobel lecture, 8. December. 1984. Biosci. Rep. 5:353-376.
28. Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD. 2000. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J. Leukoc. Biol. 67:471-478.
29. Brandt E, Ludwig A, Petersen F, Flad HD. 2000. Platelet-derived CXC chemokines: old players in new games. Immunol. Rev. 177:204-216.
30. Compton T, Nowlin DM, Cooper NR. 1993. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:834-841.
31. Isaacson MK, Juckem LK, Compton T. 2008. Virus entry and innate immune activation. Curr. Top. Microbiol. Immunol. 325:85-100.
32. Mayo KH, Ilyina E, Roongta V, Dundas M, Joseph J, Lai CK, Maione T, Daly TJ. 1995. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. Biochem. J. 312:357-365.
33. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M. 1993. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc. Natl. Acad. Sci. U. S. A. 90:3574-3577.
34. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafelt AB. 1995. The functional role of the ELR motif inCXCchemokinemediated angiogenesis. J. Biol. Chem. 270:27348-27357.
35. Rajagopalan L, Rajarathnam K. 2006. Structural basis of chemokine receptor function: a model for binding affinity and ligand selectivity. Biosci. Rep. 26:325-339.
36. Liu J, Thorp SC. 2002. Cell surface heparan sulfate and its roles in assisting viral infections. Med. Res. Rev. 22:1-25.
37. Yeaman MR, Bayer AS. 1999. Antimicrobial peptides from platelets. Drug Resist. Updat. 2:116-126.
38. Dürr M, Peschel A. 2002. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect. Immun. 70:6515-6517.
39. Yeaman MR, Yount NY. 2007. Unifying themes in host defence effector polypeptides. Nat. Rev. Microbiol. 5:727-740.
40. Tang YQ, Yeaman MR, Selsted ME. 2002. Antimicrobial peptides from human platelets. Infect. Immun. 70:6524-6533.
41. Krijgsveld J, Zaat SA, Meeldijk J, van Veelen PA, Fang G, Poolman B, Brandt E, Ehlert JE, Kuijpers AJ, Engbers GH, Feijen J, Dankert J. 2000. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J. Biol. Chem. 275: 20374-20381.
42. Neyts J, Snoeck R, Schols D, Balzarini J, Esko JD, Van Schepdael A, De Clercq E. 1992. Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology 189:48-58.
43. Boyle KA, Compton T. 1998. Receptor-binding properties of a soluble form of human cytomegalovirus glycoprotein B. J. Virol. 72:1826-1833.
44. Trybala E, Olofsson S, Mardberg K, Svennerholm B, Umemoto K, Glorioso JC, Bergstrom T. 2004. Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells. Antiviral Res. 62:125-134.
45. Luganini A, Giuliani A, Pirri G, Pizzuto L, Landolfo S, Gribaudo G. 2010. Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res. 85:532-540.
46. Copeland R, Balasubramaniam A, Tiwari V, Zhang F, Bridges A, Linhardt RJ, Shukla D, Liu J. 2008. Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry 47:5774-5783.
47. Baleux F, Loureiro-Morais L, Hersant Y, Clayette P, Arenzana-Seisdedos F, Bonnaffe D, Lortat-Jacob H. 2009. A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. Nat. Chem. Biol. 5:743-748.
48. Lindahl U, Kusche-Gullberg M, Kjellen L. 1998. Regulated diversity of heparan sulfate. J. Biol. Chem. 273:24979-24982.
49. Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. 1981. Studies of human plate alpha-granule release in vivo. Blood 58:607-618.
50. Lortat-Jacob H. 2009. The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr. Opin. Struct. Biol. 19:543-548.
51. WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63:52-58.
52. Nguyen LT, Chan DI, Boszhard L, Zaat SA, Vogel HJ. 2010. Structurefunction studies of chemokine-derived carboxy-terminal antimicrobial peptides. Biochim. Biophys. Acta 1798:1062-1072.
53. Herold BC, Gerber SI, Belval BJ, Siston AM, Shulman N. 1996. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J. Virol. 70:3461-3469.
54. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. 1999. A novel role for 3-Osulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13-22.
55. Shukla D, Spear PG. 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J. Clin. Invest. 108:503-510.
56. English EP, Chumanov RS, Gellman SH, Compton T. 2006. Rational development of beta-peptide inhibitors of human cytomegalovirus entry. J. Biol. Chem. 281:2661-2667.
57. Damonte EB, Matulewicz MC, Cerezo AS. 2004. Sulfated seaweed polysaccharides as antiviral agents. Curr. Med. Chem. 11:2399-2419.
58. Ghosh T, Chattopadhyay K, Marschall M, Karmakar P, Mandal P, Ray B. 2009. Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation. Glycobiology 19:2-15.
59. Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA. 2010. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob. Agents Chemother. 54:2753-2766.
60. Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, Glass CA, Wang L, Tor Y, Esko JD. 2008. Surfen, a small molecule antagonist of heparan sulfate. Proc. Natl. Acad. Sci. U. S. A. 105:13075-13080.
61. Kato D, Era S, Watanabe I, Arihara M, Sugiura N, Kimata K, Suzuki Y, Morita K, Hidari KI, Suzuki T. 2010. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein. Antiviral Res. 88:236-243.